Skip to main content
Premium Trial:

Request an Annual Quote

Shares in CombiMatrix Jump 6.6 Percent as New Dx Unit Gains Traction

NEW YORK, July 12 (GenomeWeb News) - Shares in CombiMatrix were up 6.58 percent, or $.15, at $2.43 in mid-afternoon trading after the company said its newly created diagnostics subsidiary has begun negotiating with undisclosed potential distributors and customers.

 

As GenomeWeb News reported this morning, the wholly owned business was created to focus on microarray-based diagnostics. Specifically, the business aims to be a testing center for clinicians who wish to use CombiMatrix' array technology for certain molecular diagnostics applications.

 

CombiMatrix said it hopes the subsidiary can take advantage of US Food and Drug Administration guidelines that allow the use of homebrew microarrays in creating diagnostics, thereby generating revenue before its technology gets FDA approval. Under the FDA's home-brew rules, labs that make the diagnostic array in their facilities and test it there do not require FDA approval.

 

The unit will initially focus on developing cancer diagnostics using the CombiMatrix's Desk Top Synthesizer, which was designed to enable researchers to build their own chips, Bret Undem, vice president of research at the Mulkiteo, Wash.-based CombiMatrix, said in May.

  

The unit has "begun efforts to build our first cancer diagnostic products based on CombiMatrix's CustomArray technology," Matthew Watson, CMD CEO, said in a statement today. He added that CMD has applied for "all appropriate licenses," including its Clinical Laboratory Improvement Amendment certification, which would enable its homebrew business. "We have also begun strategic alliance discussions with potential distributors and customers," Watson said.

 

Additional details were not disclosed.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.